Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Unusually-High Trading Volume – What’s Next?

Posted by Latisha Jones on Mar 2nd, 2026

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY – Get Free Report) saw strong trading volume on Monday . 531,197 shares were traded during trading, an increase of 170% from the previous session’s volume of 196,496 shares.The stock last traded at $31.9450 and had previously closed at $33.61.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on CHGCY. Smbc Nikko Sec. raised shares of Chugai Pharmaceutical to a “strong-buy” rating in a research report on Wednesday, February 25th. UBS Group raised shares of Chugai Pharmaceutical to a “strong-buy” rating in a research report on Tuesday, January 27th. Two analysts have rated the stock with a Strong Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Strong Buy”.

Check Out Our Latest Analysis on CHGCY

Chugai Pharmaceutical Stock Performance

The stock’s fifty day moving average price is $28.29 and its 200-day moving average price is $25.47. The firm has a market cap of $105.77 billion, a PE ratio of 36.94 and a beta of 0.60.

Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last issued its quarterly earnings data on Thursday, January 29th. The company reported $0.25 EPS for the quarter. Chugai Pharmaceutical had a net margin of 34.47% and a return on equity of 22.00%. The firm had revenue of $2.25 billion for the quarter. Sell-side analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current fiscal year.

About Chugai Pharmaceutical

(Get Free Report)

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.